Abstract
Most contemporary clinical trials of new technologies collect health-related quality of life (HRQoL) data that can be used to generate utility values. Such data can be used to estimate differences in quality-adjusted life-year (QALY) gains in economic evaluations alongside clinical trials. However, such evaluations rarely represent all important differences in costs and outcomes, and cost-effectiveness models are commonly used to extrapolate beyond a trial’s time horizon to estimate longer-term costs and QALY gains [1].
HRQoL data collected in clinical trials are potentially important data sources to inform heath state utility values (HSUVs) that are key inputs to most cost-effectiveness models. In the ideal, the utility data collected in a clinical trial provide robust, sensitive preference-based estimates of all the HSUVs required to populate a cost-effectiveness model. Key issues that complicate the estimation of HSUVs using trial data include the sensitivity of selected preference-based measures (PBMs) to meaningful differences in HRQoL between health states, the small samples of utility data for some of the health states represented in cost-effectiveness models and the timing of the collection of utility data in clinical trials. As a result, separate utility studies may be required to more appropriately inform the HSUVs required to populate cost-effectiveness models.
HRQoL data collected in clinical trials are potentially important data sources to inform heath state utility values (HSUVs) that are key inputs to most cost-effectiveness models. In the ideal, the utility data collected in a clinical trial provide robust, sensitive preference-based estimates of all the HSUVs required to populate a cost-effectiveness model. Key issues that complicate the estimation of HSUVs using trial data include the sensitivity of selected preference-based measures (PBMs) to meaningful differences in HRQoL between health states, the small samples of utility data for some of the health states represented in cost-effectiveness models and the timing of the collection of utility data in clinical trials. As a result, separate utility studies may be required to more appropriately inform the HSUVs required to populate cost-effectiveness models.
| Original language | English |
|---|---|
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | Pharmacoeconomics |
| Volume | 35 |
| Issue number | Suppl 1 |
| DOIs | |
| Publication status | Published - 1 Dec 2017 |
| Externally published | Yes |
Keywords
- QALY
- quality of life
- economic evaluation
- Heath State Utility Values (HSUVs)